The consistent experimental and clinical evidence present in this study predicts that the number of MPNST cases in NF1 patients is actually much lower due to the antagonistic role of the NF1+/− microenvironment, considering the size and number of pNF in NF1 patients. The gene discussed is NF1; the disease is neurofibromatosis type 1.